10-Q: Nutra Pharma Faces Going Concern Amidst Deepening Losses

Nutra Pharma Corp. reported a widened net loss for Q2 2024 and a significant accumulated deficit, raising substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the three months ended June 30, 2024, increased by 31.48% to $367,139, compared to $279,246 for the same period in 2023.
• Net loss for the six months ended June 30, 2024, decreased by 8.92% to $794,073, compared to $871,806 for the same period in 2023.
• Total current assets were $359,886 at June 30, 2024, a slight increase from $314,060 at December 31, 2023.
• Total current liabilities increased to $15,000,263 at June 30, 2024, from $14,171,637 at December 31, 2023.
• The company has an accumulated deficit of $75,739,547 at June 30, 2024.
• A working capital deficit of $14,640,377 and a stockholders' deficit of $14,558,881 were reported at June 30, 2024.
• Net sales to unrelated customers decreased by 1.31% for the three months and 16.35% for the six months ended June 30, 2024, compared to the prior year periods.
• Net sales to related party Avini Health decreased significantly by 67.32% for the three months and 66.33% for the six months ended June 30, 2024, due to Avini manufacturing its own products.
• Gross profit margin for the three months ended June 30, 2024, improved to 61.99% from 51.33% in 2023, primarily due to lower manufacturing costs associated with related party sales, despite a $15,000 reserve for undelivered venom.
• Gross profit margin for the six months ended June 30, 2024, declined to 55.87% from 58.68% in 2023, primarily due to a $30,000 reserve for undelivered venom and slow-moving inventory.
• Selling, general and administrative expenses increased by 2.77% for the three months but decreased by 8.81% for the six months ended June 30, 2024, influenced by new officer compensation, legal fees, and reduced office costs under the Avini arrangement.
• The company has no cash or cash equivalents balances as of June 30, 2024, and December 31, 2023.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by significant and increasing deficits, no cash, declining revenues, and a going concern warning. While there are some positive gross margin trends and legal settlements, these are overshadowed by fundamental liquidity and operational challenges, and heavy reliance on dilutive or defaulting debt. The future outlook is highly contingent on securing additional, currently uncertain, financing.

Positives

• Gross profit margin for the three months ended June 30, 2024, improved to 61.99% from 51.33% in the prior year, reflecting lower manufacturing costs associated with related party sales.
• Selling, general and administrative expenses decreased by $58,415 (8.81%) for the six months ended June 30, 2024, due to reduced payroll and office costs under the new arrangement with Avini, and lower legal fees following a major lawsuit settlement.
• A net gain of $13,920 on settlement of debts and accrued expenses was recognized for the six months ended June 30, 2024, primarily from a debt settlement through common stock issuance.
• The company settled a promissory note litigation with CSA 8411, LLC for $125,000, resulting in a gain on settlement of $53,526 to be recognized upon full payment.

Negatives

• The company reported a net loss of $367,139 for the three months ended June 30, 2024, an increase of 31.48% from the prior year.
• The company has an accumulated deficit of $75,739,547 at June 30, 2024.
• A significant working capital deficit of $14,640,377 and a stockholders' deficit of $14,558,881 exist at June 30, 2024.
• Net sales to unrelated customers decreased by 16.35% for the six months ended June 30, 2024, to $89,422.
• Net sales to related party Avini Health decreased by 66.33% for the six months ended June 30, 2024, to $71,708, as Avini began manufacturing its own products.
• The company has a significant amount of indebtedness in default, with $4,239,923 of convertible notes payable in default at June 30, 2024, and $4,718,444 remaining in default at the report date.
• The company has no cash or cash equivalents as of June 30, 2024, and December 31, 2023.
• A reserve for supplier advances for future venom purchases increased by $30,000 for the six months ended June 30, 2024, impacting gross margin.
• Interest expense, including related party interest, remains substantial at $173,651 for the six months ended June 30, 2024.
• Loss from change in fair value of convertible notes and derivatives increased to $122,990 for the six months ended June 30, 2024, from $90,185 in the prior year.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to recurring significant losses, accumulated deficit, and working capital deficit.
• The company does not have sufficient cash to sustain operations for the next twelve months and requires additional financing.
• Reliance on debt and equity funding has not been sufficient to execute the business plan.
• The company's common stock is on the OTC Market Group's Expert Market, limiting its ability to raise capital through proprietary broker-deal quotes.
• Failure to successfully develop and commercialize products from research and development activities.
• Intense competition in the biotechnology area could negatively impact operations and market position.
• Failure to successfully execute planned partnering and out-licensing of products or technologies.
• The recent economic downturn and related credit and financial market crisis may adversely affect the ability to obtain financing.
• Biotechnology industry-related litigation is substantial and may continue to rise, leading to greater costs.
• The decline in sales to Avini Health, as Avini has begun manufacturing its own products, is expected to reduce revenues and may require developing new customer relationships or product lines.
• Failure to comply with extensive legal/regulatory requirements affecting the healthcare industry could lead to increased costs, penalties, and business losses.
• The company has a significant amount of indebtedness in default, which could lead to further legal actions or unfavorable restructuring terms.
• The potential for substantial dilution to existing shareholders if additional equity capital is raised to fund working capital requirements.

Future Outlook

The company plans to re-engage in the regulatory approval process for Nyloxin in Canada in 2026, contingent on adequate funding. It also aims to initiate Phase I/II trials for RPI78M in Pediatric Multiple Sclerosis in 2026, also dependent on financing. Marketing efforts for existing products are expected to increase as sales grow. Sales to Avini Health are expected to decline beginning in 2024 as Avini manufactures its own products, requiring the company to develop new customer relationships or product lines. The company estimates requiring approximately $600,000 to fund existing operations over the next twelve months.

Management Comments

• "We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern."
• "We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form."
• "Our plan is to attempt to secure adequate funding through notes payable until sales of our pain products are adequate to fund our operations."
• "Our goal is to initiate these trials [for RPI78M] in 2026."
• "As sales increase, we plan to begin marketing more aggressively to increase the sales and awareness of our products."

Industry Context

The company operates in the biotechnology and homeopathic drug industry, focusing on pain relief products and drug discovery. The industry is intensely competitive and subject to extensive legal and regulatory requirements. The company's strategy to develop non-opioid pain relievers aligns with a broader industry trend to address concerns about opioid and NSAID overuse. The pursuit of Orphan Status for RPI78M in pediatric MS indicates a focus on niche markets with potentially faster approval timelines and funding opportunities, a common strategy for smaller biotech firms. However, the company's significant financial distress and reliance on debt funding contrast sharply with the capital-intensive nature of drug development and commercialization in the biotech sector, where robust funding is typically critical for success.

Comparison to Industry Standards

• The company's lack of cash and significant accumulated deficit are well below industry standards for a publicly traded biotechnology company, which typically require substantial capital for R&D and commercialization.
• The reliance on notes payable and convertible debt, many of which are in default, indicates a distressed financial position, unlike more stable industry peers who often secure funding through larger equity rounds or non-dilutive partnerships.
• The company's presence on the OTC Market Group's Expert Market limits its access to capital compared to companies listed on major exchanges, which is a significant disadvantage in a capital-intensive industry.
• While the development of RPI78M for pediatric MS with Orphan Status is a positive, the stated goal to initiate Phase I/II trials in 2026, contingent on funding, suggests a slower pace of development compared to well-funded biotech companies that can accelerate clinical timelines.
• The decline in sales to a major related party (Avini Health) highlights a vulnerability in revenue concentration and the need for diversification, which is a common challenge for smaller companies but typically managed more proactively by industry leaders.

Management Changes

Corporate Governance

Legal Proceedings

• CSA 8411, LLC v. Nutra Pharma Corp.: A lawsuit filed on October 12, 2018, to recover $100,000 allegedly owed under an amended promissory note. A settlement agreement was reached on May 19, 2025, to resolve the total obligation for $125,000, payable with an initial $35,000 and nine monthly payments of $10,000. A default could lead to a $400,000 consent judgment.
• Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus: A lawsuit filed on September 28, 2018, alleging fraud, false statements, and failure to file required registration statements and public disclosures. A final judgment was issued in July 2024, ordering the company to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty. The company had accrued $680,235 for this settlement.

Related Party Transactions

• Net sales to Avini Health, a company owned by the former CEO, decreased significantly by 66.33% for the six months ended June 30, 2024, to $71,708, as Avini began manufacturing its own products.
• The company relocated its operations to a Boca Raton facility leased by Avini, using the facility rent-free and sharing space/resources, with Avini paying all lease and office-related expenses.
• Convertible notes payable totaling $253,000 were reclassified to 'due to officers' upon Michael Flax's appointment as CEO in March 2024.
• Accrued interest of $178,971 was owed to a director as of June 30, 2024, on a $200,000 loan from 2010, which is in default.
• Balances due to officers totaled $1,108,375 at June 30, 2024, and accrued payroll due to officers was $1,504,790.
• The company had fully reserved receivables of $177,261 from companies owned by the former CEO, Rik Deitsch.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity raises and conversions of existing convertible debt, especially given the large number of antidilutive securities.
• Shareholders are impacted by the substantial accumulated deficit and ongoing net losses, eroding shareholder value.
• Creditors, particularly holders of defaulted notes, face uncertainty regarding repayment and may pursue further legal action.
• Employees and officers have significant accrued payroll and loans due to them, indicating potential compensation deferrals or financial strain.
• The company's ability to continue operations and fulfill its mission is at risk, impacting all stakeholders.
• The SEC lawsuit and associated penalties reflect regulatory scrutiny and potential reputational damage.

Next Steps

• Attempt to secure adequate funding through notes payable until sales of pain products are sufficient to fund operations.
• Re-engage in the regulatory approval process for Nyloxin in Canada in 2026.
• Complete human clinical studies comparing Nyloxin Extra Strength to prescription pain relievers, contingent on adequate financing.
• Initiate Phase I/II trials for RPI78M in Pediatric Multiple Sclerosis in 2026, contingent on adequate financing.
• Increase marketing efforts for existing products as sales increase.
• Develop new customer relationships or product lines to offset declining sales to Avini Health.
• Continue negotiations for settlement of various defaulted convertible notes and promissory notes.
• Make nine monthly payments of $10,000 each, following an initial $35,000 payment, as part of the CSA 8411, LLC settlement agreement.

Key Dates

Recommendation

The company's financial position is extremely precarious, marked by a severe going concern warning, no cash, substantial and increasing deficits, and a significant amount of defaulted debt. Revenues are declining, particularly from a key related party, and the ability to fund future operations and R&D is highly uncertain. The stock is on the OTC Expert Market, limiting liquidity and capital access. While some legal settlements offer minor relief, the overall financial health and operational viability present an exceptionally high risk profile, making it an unsuitable investment for seasoned investors or institutions.

Keywords

Biotechnology, Pharmaceuticals, Pain relief, Homeopathic drugs, SEC filing, Going concern, Net loss, Convertible notes, Debt default, OTC Market, ReceptoPharm, Nyloxin, Pet PainAway, Luxury Feet, Equine Pain-Away, Drug discovery, RPI78M, RPIMN, Orphan status